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Background
One of the challenges for management of drug hyper-
sensitivity reactions (DHR) is to detect a culprit drug.
Although measures of interferon IFN-gamma produc-
tion by patients’ drug-specific T cells have been the
widely utilized cytokine assay, a systematic comparison
of different methods has not yet been reported.
Method
A total of 16 patients with clinically well-established
maculopapular exanthema due to antiepileptic drugs
hypersensitivity in remission state and 15 drug-exposed
control donors without DHR were included to the
study. Peripheral blood mononuclear cells of investi-
gated individuals were isolated and cultured under
defined conditions with drugs. IFN-gamma production
was measured with electrochemiluminescence array
assay and ELISA (cytokine level in cell culture superna-
tant), ELISpot (cytokine secreting cells), flow cytometry
(intracellular staining in CD3+ CD4+ cells).
Results
IFN-gamma production could be demonstrated in 13 of 16
patients using electrochemiluminescence assay (sensitivity
81%), in 8 of 16 patients using ELISA (sensitivity 50%), in
6 of 16 and 7 of 16 patients using ELISpot (sensitivity
46%) and flow cytometry (sensitivity 57%), respectively.
The sensitivity of combined measurements of drug-speci-
fic IFN-gamma by ELISpot, ELISA and flow cytometry
achieved 88%. Healthy controls showed negative drug-spe-
cific IFN-gamma production in contrast to individuals
with a known sensitivity in all tested read-out systems.
The assays demonstrated a test specificity of 100% (elec-
trochemiluminescence), 93% (ELISA), 100% (ELISpot) and
100% (flow cytometry).
Conclusion
Analysis of drug-specific IFN-gamma production by
means of different assays proved a useful and reliable
approach for the in vitro detection of drug hypersensitiv-
ities in the investigated population. Electrochemilumines-
cence array assay offers distinct advantage over the other
tested assays, including a greater sensitivity, but its avail-
ability is limited because of the costs. Also combining dif-
ferent assays may be a feasible approach to identify the
causative drug of DHR.
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